Cargando…

Activation of TGF-beta signalling in breast cancer metastatic cells

Detalles Bibliográficos
Autores principales:	Giampieri, S, Sahai, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300699/ http://dx.doi.org/10.1186/bcr1880

Ejemplares similares

Is transforming growth factor beta signalling required for breast cancer metastatic cell motility?
por: Giampieri, S, et al.
Publicado: (2006)

Transforming growth factor beta (TGFβ) signaling is regulated at the pocket region of primary cilia
por: Christensen, S, et al.
Publicado: (2012)

Oral vinorelbine in metastatic breast cancer
por: Conte, PF, et al.
Publicado: (2005)

Stromal and epithelial TGF-β signaling in mammary tumorigenesis
por: Moses, HL, et al.
Publicado: (2005)

Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility
por: Giampieri, Silvia, et al.
Publicado: (2009)

Aberrant activation of Notch signalling in human breast cancer
por: Stylianou, S, et al.
Publicado: (2006)

Association of gene variants in the TGF-beta signalling pathways with invasive breast cancer risk
por: Scollen, S, et al.
Publicado: (2008)

Transforming growth factor-beta co-receptor endoglin suppresses breast cancer invasion and metastasis
por: Henry, LA, et al.
Publicado: (2010)

Superior antiviral and antiproliferative activity of IFN-beta vs. IFN-alpha in primary ATL cells occurs downstream of STAT1 signaling
por: Khouri, Ricardo, et al.
Publicado: (2014)

Can high-frequency ultrasound predict metastatic lymph nodes in patients with invasive breast cancer?
por: Clough, GR, et al.
Publicado: (2004)

Pathological features and patterns of metastatic disease in locally advanced inflammatory and non-inflammatory breast cancer
por: Mvere, MZ, et al.
Publicado: (2009)

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

Roles of beta-arrestin1/2 in prostaglandin-mediated signaling and tumor development
por: Langenbach, Robert, et al.
Publicado: (2010)

Use of mouse models to validate and therapeutically target transforming growth factor beta as an important player in breast cancer progression
por: Wakefield, LM, et al.
Publicado: (2003)

Ablation for metastatic lung cancer
por: de Baère, Thierry
Publicado: (2015)

Inhibition of IGF signalling pathway in MDA-MB-231 triple negative breast cancer cells
por: Chandran, S, et al.
Publicado: (2012)

Transcriptional regulation of tenascin‐W by TGF‐beta signaling in the bone metastatic niche of breast cancer cells
por: Chiovaro, Francesca, et al.
Publicado: (2015)

Foodborne cereulide causes beta cell dysfunction and apoptosis
por: Vangoitsenhoven, Roman, et al.
Publicado: (2014)

Stem cells in normal breast development and breast cancer
por: Wicha, MS, et al.
Publicado: (2003)

Integrin-mediated signal transduction in transgenic mouse models of human breast cancer
por: White, DE, et al.
Publicado: (2003)

CCR6 mediates the intracellular HIV inhibitory activity of human beta-defensin 2
por: Sun, Lingling, et al.
Publicado: (2006)

Synergy between the erbB and transforming growth factor beta signaling networks: implications for molecular therapeutics in human neoplasia
por: Arteaga, CL
Publicado: (2003)

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms
por: Kotlan, Beatrix, et al.
Publicado: (2014)

Steroid regulation of breast cancer cell proliferation
por: Sutherland, RL
Publicado: (2003)

Stem cells in human breast development and cancer
por: Wicha, M, et al.
Publicado: (2005)

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
por: Baselga, J, et al.
Publicado: (2011)

Translational breast cancer research in luminal breast cancer
por: Dowsett, M
Publicado: (2011)

Brain lesions in oncology patients: recognising metastatic versus non metastatic lesions
por: Rich, Philip
Publicado: (2015)

Targeting the cell cycle for prognosis and therapy of breast cancer
por: Keyomarsi, K, et al.
Publicado: (2005)

Predictive factors in breast cancer
por: Klijn, J, et al.
Publicado: (2000)

Epistasis and the sensitivity of phenotypic screens for beta thalassaemia
por: Penman, Bridget, et al.
Publicado: (2014)

S111: BRAIN PERFUSION CHANGES IN BETA-THALASSEMIA
por: Manara, R, et al.
Publicado: (2022)

S106: LONG-TERM FOLLOW-UP OF BETA-THALASSEMIA PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL GENE THERAPY
por: Marktel, S, et al.
Publicado: (2022)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

Functional characterization of mammary stem cells in development and breast cancer
por: Rosen, JM, et al.
Publicado: (2003)

Epigenetics of breast cancer
por: Esteller, M
Publicado: (2011)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Long-term survival of interval breast cancers in breast cancer screening in Wales
por: Fong, YF, et al.
Publicado: (2012)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Circulating tumor cells and novel biomarkers for prognostic and biological of breast cancer
por: Cristofanilli, M
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_bicc6fjskvcjb5aeik529mas4b